GO PRP: Assessing the Efficacy of Intra Articular Injection of Platelets Rich Plasma for Gonarthrosis Treatment in Routine Care
Study GO-PRP: Assessing the Efficacy of Intra Articular Injection of Platelets Rich Plasma for Gonarthrosis Treatment in Routine Care
調査の概要
詳細な説明
The main objective is to get a 50% proportion of responders defined by answers "absent" or "light" in the KOOS questionnaire on questions about pain and difficulty walking on flat ground.
Secondary objectives include the safety validation of the use of PRP (prepared standardized manner by means of a given medical device) as second-line standard of care for osteoarthritis by the introduction of a systematic monitoring; and the feasibility of the health care system dedicated to the treatment of knee osteoarthritis by autologous PRP.
Furthermore, the secondary objectives are to monitor and follow the evolution of pain (VAS) and the knee function (KOOS score) at 1 month, 3 months, 6 months. Evaluation of MRI will be performed within 15 days prior (inclusion visit) injection and 6 months to assess the cartilage thickness and visualize a regenerative effect.
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Marseille、フランス、13008
- Hopital Saint Joseph
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Men and women 20 to 80 years
- Gonarthrosis diagnostic objectified by the criteria of the American College of Rheumatology
- Joint pain for more than 6 months
- Answer "moderate" to the question about pain walking on flat ground
- Answer "moderate" to the question about trouble walking on flat ground
- Osteoarthritis stage 2 or 3 on the scale of Kellgren Lawrence (objectified radiography) within 6 months previous inclusion
- Axial deformation of less than or equal to 5 ° lower limbs
- Informed consent signed by the patient
- HB> 10g / dl
- Beta-HCG negative at baseline
- Ability to perform the procedures in the follow-up (50 not walk on a flat surface and up / down stairs).
- Being affiliated to a system of health insurance
Exclusion criteria:
- Axial deformation > 5 °
- Ligamentous instability
- Significant injuries or target knee or knee surgery contralateral side in 12 months previous the inclusion visit
- Ligament reconstruction in the 12 months précédants the inclusion visit
- Need a cane or assistance to move
- BMI> 35
- Thrombocytopenia <150 G / L
- Thrombocytosis> 450 G / L
- Known thrombopathy
- Anemia HB <10g / dl
- Active infections to HIV 1 and 2, Agp24, HCV Ab, Ag and HbS AcHbc, Ac HTLV I and II, TPHA
- Chronic treatment with corticosteroids per os or older than 2 weeks
- Injection intra-articular corticosteroid of less than 2 months
- Intra-articular injection of hyaluronic acid of less than 6 months
- NSAIDs or antiplatelet agent of less than 15 days
- Inability to stop NSAIDs (including aspirin) 15 days before the injection and the week following the injection
- Fever or recent illness
- Autoimmune diseases
- Inflammatory arthritis
- Immune deficiency
- Infectious diseases
- Pregnant women
- Adults legally protected (under guardianship and trusteeship)
- People simultaneously participating in other biomedical research16. Inability
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:knee osteoarthritis patients.
therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
|
one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
to monitor and follow the evolution of pain
時間枠:prior,1 month, 3 months, 6 months
|
VAS to monitor and follow the evolution of pain
|
prior,1 month, 3 months, 6 months
|
|
to monitor and follow the evolution of the knee function
時間枠:prior,1 month, 3 months, 6 months
|
(KOOS score)
|
prior,1 month, 3 months, 6 months
|
|
Evaluation of MRI
時間枠:prior,1 month, 3 months, 6 months
|
Evaluation will be performed within 15 days prior (inclusion visit) injection and 6 months to assess the cartilage thickness and visualize a regenerative effect.
|
prior,1 month, 3 months, 6 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。